SEARCH

Current Edition

AstraZeneca and Lilly’s Alzheimer’s drug fails trial

The battle to develop a drug to treat Alzheimer’s disease has been dealt a blow following disappointing phase 3 trial results. AstraZeneca and Eli Lilly’s …

13 June 2018 Europe 3 Alzheimer

Continue Reading →

Early findings from a phase 3 clinical trial report promising results

The interim results from a phase 3 clinical trial testing DCVax®-L, a dendritic cell treatment, show increased overall survival for patients with glioblastoma. Dendritic cells …

31 May 2018 Europe 3 clinical

Continue Reading →

Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis

U.S. regulatory submission for patients ages 12-17 planned for third quarter 2018 A pivotal Phase 3 trial evaluating Dupixent® (dupilumab) to treat moderate-to-severe atopic dermatitis …

16 May 2018 Europe 3 adolescents

Continue Reading →

Journal for Clinical Studies

Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.

SEARCH

MENU

Current Edition

AstraZeneca and Lilly’s Alzheimer’s drug fails trial

Early findings from a phase 3 clinical trial report promising results

Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis

Journal for Clinical Studies